ELDN
Eledon Pharmaceuticals, Inc. [ELDN] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
ELDN Stock Summary
Top ELDN Correlated Resources
ELDN
Top 10 Correlated ETFs
ELDN
Top 10 Correlated Stocks
ELDN
In the News
ELDN Financial details
Company Profile
- Volume Average 75.82K
- Market Capitalization 40.89M
- Employee 20
- CEO Dr. David-Alexandre C. Gros M.D., Ph.D.
- Headquarters Irvine,CA,US
- IPO Date 2014-09-17
-
Website
https://eledon.com 
Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
